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Tobacco dependence is a global epidemic and a major preventable cause 
of morbidity and mortality. The World Health Organization reported that 
nearly 6 million tobacco-related deaths occur annual ly.[1] Despite the 
well-known benefits of smoking cessation, it remains a challenge for 
many smokers who attempt to quit. Approximately 70% of smokers 
want to discontinue smoking;[2] however, only 3 - 5% of those who 
attempt to do so without assistance remain abstinent in the long 
term.[3] Behavioural interventions and pharmacotherapy are effective 
methods in smoking cessation,[4] and when combined, are even more 
effica cious.[5] Commonly used pharmacotherapies include nicotine 
replacement therapy (NRT), bupropion and varenicline. All have been 
proven to be efficacious to varying degrees.
Studies investigating factors that predict smoking cessation success 
have identified the following: male gender, older age, older age at 
initiation of smoking, lower nicotine dependency, lower exhaled 
carbon monoxide levels, fewer cigarettes smoked per day and higher 
confidence with regard to quitting (self-efficacy). Heavier smokers 
and smokers with a high nicotine dependency in particular are 
more likely to continue smoking.[6-15] A tobacco user who smokes 
at least 20 cigarettes per day is generally considered to be a heavy 
smoker. The level of nicotine dependence may be assessed with the 
Fagerström test for nicotine dependence (FTND) – a frequently used 
questionnaire scored out of 10, with a score of at least 7 denoting 
high dependency.[16] Reasons for successful cessation include health 
concerns and the high cost of cigarettes.[17] The motivation for 
continued smoking may also contribute – smoking for pleasure 
or reward (positive reinforcement), or to relieve a negative state 
(negative reinforcement).[18]
A recent study reported that combining varenicline and bupropion 
improved abstinence rates in heavier smokers and in persons with 
a high nicotine dependency.[19] This suggests that combination 
therapies may improve success rates in these difficult groups. 
In a recent randomised controlled trial (RCT), we established that 
varenicline combined with NRT was more effective than varenicline 
alone, with a favourable safety profile.[20] We performed a post-hoc 
analysis of the data from the original RCT to identify the indepen-
dent predictors of successful abstinence at 12 and 24 weeks after the 
target quit date. The objective was to assist healthcare workers to 
select interventions according to the characteristics of the individual 
smoker to improve their chances of success.
Methods
Study design
We performed a post-hoc analysis of a study dataset prospectively 
collected from April 2011 to October 2012 at seven sites throughout 
South Africa (SA). The study was conducted in accordance with 
the principles outlined in the Declaration of Helsinki, and local and 
international Good Clinical Practice guidelines. Ethical approval was 
obtained from the Health Research Ethics Committee of Stellenbosch 
University (ref. no. S15/02/029). The original study methods and 
This open-access article is distributed under 
Creative Commons licence CC-BY-NC 4.0.
Predictors of treatment success in smoking 
cessation with varenicline combined with nicotine 
replacement therapy v. varenicline alone 
F Noor,1 MB ChB, MSc; C F N Koegelenberg,1 MB ChB, MMed (Int), FCP (SA), FRCP (UK), Cert Pulm (SA), PhD; T M Esterhuizen,2 MSc; 
E M Irusen,1 MB ChB, FCP (SA), PhD
1 Division of Pulmonology, Department of Medicine, Stellenbosch University and Tygerberg Academic Hospital, Cape Town, South Africa
2 Centre for Evidence-based Health Care, Stellenbosch University, Cape Town, South Africa
Corresponding author: C F N Koegelenberg (coeniefn@sun.ac.za)
Background. Identification of the predictors of treatment success in smoking cessation may help healthcare workers to improve the 
effectiveness of attempts at quitting. 
Objective. To identify the predictors of success in a randomised controlled trial comparing varenicline alone or in combination with 
nicotine replacement therapy (NRT).
Methods. A post-hoc analysis of the data of 435 subjects who participated in a 24-week, multicentre trial in South Africa was performed. 
Logistic regression was used to analyse the effect of age, sex, age at smoking initiation, daily cigarette consumption, nicotine dependence, 
and reinforcement assessment on abstinence rates at 12 and 24 weeks. Point prevalence and continuous abstinence rates were self-reported 
and confirmed biochemically with exhaled carbon monoxide readings.
Results. The significant predictors of continuous abstinence at 12 and 24 weeks on multivariate analysis were lower daily cigarette 
consumption (odds ratio (OR) 1.86, 95% confidence interval (CI) 1.21 - 2.87, p=0.005 and OR 1.83, 95% CI 1.12 - 2.98, p=0.02, respectively) 
and older age (OR 1.52, 95% CI 1.00 - 2.31, p=0.049 and OR 1.79, 95% CI 1.13 - 2.84, p=0.01, respectively). There was no difference in the 
predictors of success in the univariate analysis, except that older age predicted point prevalence abstinence at 12 weeks (OR 1.47, 95% CI 1.00 
- 2.15, p=0.049). The findings were inconclusive for an association between abstinence and lower nicotine dependence, older age at smoking 
initiation and positive reinforcement.
Conclusion. Older age and lower daily cigarette consumption are associated with a higher likelihood of abstinence in patients using 
varenicline, regardless of the addition of NRT.
S Afr Med J 2018;108(1):45-49. DOI:10.7196/SAMJ.2018.v108i1.12671
46       January 2018, Vol. 108, No. 1
RESEARCH
outcomes have been described elsewhere.[20] In the original study, 
446 adult smokers were randomised to receive either varen i -
cline 1 mg twice daily with active nicotine patches 15 mg per day 
(combination therapy) or varenicline twice daily with placebo 
patches (monotherapy) for 12 weeks, and were followed up for a 
further 12 weeks.
Study procedures and assessment
In the current analysis, all randomised participants who were 
administered at least one dose of both medications were included 
in the study population. They were categorised by specific baseline 
characteristics, including age, sex, age at smoking initiation, cigar-
ette consumption per day, nicotine dependence as measured by the 
FTND and motivation for continued smoking using the reinforce-
ment assessment, and were followed up until weeks 12 and 24. The 
measures of cessation included 7-day point prevalence abstinence, 
referring to the preceding 7 days, and continuous abstinence – a 
prolonged period of at least 4 weeks before the assessment date. 
At week 12, the 7-day point prevalence abstinence rate (PPAR) and 
the 4-week continuous abstinence rate (CAR) for weeks 9 - 12 were 
evaluated. At week 24, the 7-day PPAR and CAR for weeks 9 - 24 were 
also measured. Abstinence from tobacco was self-reported using the 
Nicotine Use Inventory (NUI), which evaluates tobacco or nicotine 
use (other than that provided) since the last contact and the preced-
ing 7 days. This was biochemically confirmed by exhaled carbon 
monoxide measurements of ≤10 parts per million. Participants who 
missed the visits at weeks 12 and 24 were considered smokers at those 
time points, and those who discontinued the study or were lost to 
follow-up were also considered smokers.
Statistical aspects
The data were analysed using Stata version 13.1 (StataCorp., USA). 
Univariate logistic regression was used to do a crude analysis of the 
entire study population to identify predictors of abstinence for each 
of the four outcomes. Participants for whom the relevant baseline 
data were missing, were excluded from that particular category for 
univariate analysis as per protocol.
Multivariate logistic regression was used to measure the association 
between all the baseline characteristics and abstinence rates at 
weeks 12 and 24, adjusting for the treatment received. To include 
all participant data in the models for multivariate analysis, missing 
data were coded as missing and included in the models as a separate 
category. Odds ratios (ORs) and 95% confidence intervals (CIs) were 
calculated and statistical significance was indicated at p˂0.05.
Results
A total of 446 participants were randomised, 435 of whom were 
included – 216 in the combination therapy arm, and 219 in the mono-
therapy arm. Their baseline characteristics have been reported else-
where.[20] No statistically significant differences in baseline predictors 
were found between the participants in the active treatment group 
and those in the placebo group. Missing baseline data were minimal 
and comparable across treatment arms (<2%).
The short-term (7-day point prevalence) and long-term (con-
tinuous) abstinence rates in each treatment arm according to baseline 
characteristics are shown in Table 1. In keeping with our previous 
findings, the active group had a higher abstinence rate than the pla-
cebo group across all categories.[20] 
In the univariate analysis conducted at 12 and 24 weeks, CARs 
were significantly higher in light smokers than in heavy smokers at 
both time points, and in older participants than in those <50 years of 
age at the 24-week time point (Table 2). These associations remained 
significant in the multivariate analysis. The only predictor of PPAR 
was younger age – at 12 weeks. In the sample, heavily nicotine-depen-
dent participants were more likely to continue smoking than those 
who were less nicotine dependent; however, this difference was not 
statistically significant, indicating no population differences. No 
other factors significantly predicted successful smoking cessation, 
including sex, age at smoking initiation and motivation for continued 
smoking, i.e. the reinforcement assessment.
The multivariate analysis did not markedly change the ORs for 
all variables, except for identifying younger age as a predictor of the 
12-week CAR.
Participants who started smoking after the age of 20 had a 
relatively poorer response on varenicline alone (CAR 22.2%) than 
those on combination therapy (CAR 39.1%) (p<0.01).
Discussion
The original study confirmed that the addition of NRT improved 
smoking cessation success at both time points. The only other 
significant predictors of success identified in the current analysis 
were older age and lower daily cigarette consumption. 
The reasons for smoking cessation, self-efficacy (a participant’s 
belief in his/her ability to succeed) and level of motivation were 
not assessed, but it may be that older persons are more likely to 
be motivated to quit because of health concerns. Younger persons 
may consider future opportunities to quit and be less committed 
or motivated.[11] Preparedness for the challenges of tobacco 
abstinence was not assessed, but quit attempts were well supported 
by smoking cessation counselling during all visits before and after 
quitting.
The finding that heavier smokers had lower abstinence rates 
than those who smoked fewer cigarettes per day is in keeping with 
previous research;[7,8,10-12] however, it contrasts with a recent study, 
where a combination of varenicline and bupropion improved 
abstinence in heavy smokers and in those who were more nicotine 
dependent.[19] This may be due to the average daily cigarette 
consumption in this study population being lower, as was the 
average FTND. The data from our study did not suggest that 
combination therapy (varenicline and NRT) conferred any benefit 
to heavy and more-dependent smokers.
Unlike previous research, which indicated that lower 
levels of nicotine dependence were associated with increased 
abstinence,[7,9-11,14] we did not observe this. We investigated 
whether highly dependent smokers would benefit more, but 
unexpectedly there were fewer patients with high dependence. 
Studies have also found that men are more likely to abstain 
than women;[7-10,12] however, we could not confirm this – perhaps 
because we had a greater number of female participants.
Despite the original study findings in favour of the addition of 
NRT to varenicline, we found little difference in the ORs between 
univariate and multivariate analyses, suggesting that the addition 
of nicotine replacement to varenicline did not markedly alter the 
predictors of abstinence. Baseline characteristics that predicted 
success in participants who received varenicline alone were found 
to be similar to those of the group who received both varenicline 
and NRT.
There may be other factors that contribute to smoking cessation 
success. Genetic studies of variations in the nicotine-receptor 
gene cluster CHRNA5-CHRNA3-CHRNB4 found that although 
smokers with the high-risk haplotype had a heightened response to 
pharmacotherapy, they were more likely to relapse than the low-risk 
group.[21] Recent research also found that the therapeutic response 
to a nicotine patch and varenicline is influenced by the nicotine 
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metabolite ratio (NMR), a genetically influenced biomarker 
measuring the ratio of two nicotine metabolites produced during 
smoking.[22] Participants with a normal metabolism had better 
abstinence rates when receiving varenicline, whereas those with a 
slow metabolism fared better on nicotine patches. Genetic factors 
and NMR were not assessed in the current study, but correcting 
for this ratio may change the predictors of success. From a 
behavioural science perspective, another recent study found that 
financial incentives were associated with successful smoking 
cessation and that harnessing the individual’s aversion to loss 
in a cessation programme may encourage a change in smoking 
behaviour.[23] 
Our study has limited generalisability, as we enrolled mostly 
healthy persons without a history of psychiatric illness in the 
Table 1. Abstinence rates in each treatment arm according to baseline characteristics
Baseline 
characteristics
Treatment 
arm Total
12 weeks 24 weeks
7-day PPAR,  
n (%)
CAR 9 - 12 weeks, 
n (%)
7-day PPAR,  
n (%)
CAR 9 - 24 weeks, 
n (%)
Age, years
≥50 Active 94 61 (64.89) 52 (55.32) 50 (53.19) 40 (42.55)
Placebo 90 35 (38.89) 28 (31.11) 23 (25.56) 18 (20.00)
<50 Active 122 55 (45.08) 47 (38.52) 44 (36.07) 31 (25.41)
Placebo 129 52 (40.31) 42 (32.56) 40 (31.01) 24 (18.60)
Sex
Male Active 87 43 (49.43) 38 (43.68) 34 (39.08) 28 (32.18)
Placebo 83 31 (37.35) 25 (30.12) 24 (28.92) 15 (18.07)
Female Active 129 73 (56.59) 61 (47.29) 60 (46.51) 43 (33.33)
Placebo 136 56 (41.18) 45 (33.09) 39 (28.68) 27 (19.85)
Cigarettes/day, n
≥20 Active 85 45 (52.94) 35 (41.18) 34 (40.00) 24 (28.24)
Placebo 93 31 (33.33) 20 (21.51) 21 (22.58) 12 (12.90)
<20 Active 131 71 (54.20) 64 (48.85) 60 (45.80) 47 (35.88)
Placebo 126 56 (44.44) 50 (39.68) 42 (33.33) 30 (23.81)
Level of nicotine 
dependence*
FTND ≥7 Active 12 4 (33.33) 3 (25.00) 3 (25.00) 2 (16.67)
Placebo 15 4 (26.67) 4 (26.67) 3 (20.00) 3 (20.00)
FTND <7 Active 202 111 (54.95) 95 (47.03) 89 (44.06) 68 (33.66)
Placebo 201 83 (41.29) 66 (32.84) 59 (29.35) 39 (19.40)
Age at smoking 
initiation, years
≥20 Active 46 29 (63.04) 24 (52.17) 24 (52.17) 18 (39.13)
Placebo 54 24 (44.44) 20 (37.04) 19 (35.19) 12 (22.22)
<20 Active 170 87 (51.18) 75 (44.12) 70 (41.18) 53 (31.18)
Placebo 165 63 (38.18) 50 (30.30) 44 (26.67) 30 (18.18)
Reinforcement
assessment†
NR Active 44 23 (52.27) 20 (45.45) 21 (47.73) 16 (36.36)
Placebo 52 18 (34.62) 15 (28.85) 13 (25.00) 10 (19.23)
PR Active 54 29 (53.70) 24 (44.44) 20 (37.04) 15 (27.78)
Placebo 49 24 (48.98) 16 (32.65) 18 (36.73) 10 (20.41)
NR + PR Active 95 53 (55.79) 44 (46.32) 42 (44.21) 31 (32.63)
Placebo 97 40 (41.24) 35 (36.08) 29 (29.90) 20 (20.62)
N/A Active 20 10 (50.00) 10 (50.00) 8 (40.00) 8 (40.00)
Placebo 19 5 (26.32) 4 (21.05) 3 (15.79) 2 (10.53)
PPAR = point prevalence abstinence rate; CAR = continuous abstinence rate; FTND = Fagerström test for nicotine dependence; NR = negative reinforcement (smoking to avoid a negative state); 
PR = positive reinforcement (smoking for pleasure); N/A = not applicable (never tried to quit).
*FTND not done – 2 (0.93%) in active group, and 3 (1.37%) in placebo group.
†Reinforcement assessment not done – 3 (1.39%) in active group, and 2 (0.91%) in placebo group.
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previous 2 years. Our findings are nonetheless similar to those 
of studies resembling real-life situations.[7,15] The overall attrition 
rate of 36.1% may have affected the outcomes, but attrition was 
similar across the two treatment arms (33.3% in the active arm v. 
38.8% in the placebo arm) and is comparable to that in previous 
studies. The results may have been underestimated by defining 
all participants who withdrew, defaulted on visits or were lost to 
follow-up as smokers, but this is in keeping with previous research 
and the high likelihood of treatment failure in such subjects.[19] We 
did not assess the effect of the financial cost of continued smoking 
on abstinence rates and smoking behaviour, but as our study was 
conducted during a worldwide economic recession, this may have 
influenced the predictors of successful cessation attempts. We 
could also not specifically evaluate the potential impact of the 
level of education and smoking status of participants’ partners on 
smoking cessation.
Conclusion
Advanced age and lower daily cigarette consumption are associ-
ated with a higher likelihood of abstinence in patients who receive 
vareni cline, regardless of the addition of NRT. Future studies should 
consider genetic factors, NMR, effect of personal resources, financial 
implications and local tobacco regulations, and possibly also novel 
ways of incentivising subjects.
Table 2. Predictors of smoking cessation success at weeks 12 and 24
Predictors
Univariate Multivariate*
7-day PPAR CAR 7-day PPAR CAR
OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value
12 weeks (CAR 9 - 12 weeks)
 Combination therapy 
v. monotherapy
1.76 
(1.20 - 2.57)
0.004§ 1.80
(1.22 - 2.66)
0.003§ - - - -
 Age (≥50 v. <50), 
years
1.47
(1.00 - 2.15)
0.049§ 1.40
(0.95 - 2.07)
0.09 1.49
(0.99 - 2.23)
0.056 1.52
(1.00 - 2.31)
0.049§
Sex (male v. female) 0.81
(0.55 - 1.20)
0.29 0.88
(0.59 - 1.31)
0.54 0.83
(0.55 - 1.24)
0.36 0.93
(0.62 - 1.41)
0.74
 Cigarettes/day 
(<20 v. ≥20), n†
1.31
(0.89 - 1.93)
0.17 1.78
(1.19 - 2.67)
0.005§ 1.29
(0.85 - 1.96)
0.23 1.86
(1.21 - 2.87)
0.005§
FTND (<7 v. ≥7)‡ 2.20
(0.94 - 5.15)
0.07 1.90
(0.79 - 4.6)
0.15 1.80
(0.74 - 4.35)
0.19 1.39
(0.55 - 3.52)
0.48
 Age started smoking 
(≥20 v. <20), years
1.39
(0.89 - 2.18)
0.15 1.32
(0.84 - 2.08)
0.23 1.25
(0.78 - 1.99)
0.36 1.17
(0.73 - 1.89)
0.51
 Reinforcement 
assessment, PR v. NR
1.42
(0.81 - 2.49)
0.22 1.11
(0.62 - 1.97)
0.73 1.32
(0.74 - 2.34)
0.35 1.04
(0.58 - 1.89)
0.89
 Reinforcement assess-
ment, NR + PR v. NR
1.26
(0.77 - 2.06)
0.36 1.22
(0.74 - 2.02)
0.44 1.25
(0.75 - 2.08)
0.39 1.23
(0.73 - 2.08)
0.43
24 weeks (CAR 9 - 24 weeks)
 Combination therapy 
v. monotherapy
1.91
(1.28 - 2.84)
0.001§ 2.06
(1.33 - 3.20)
0.001§ - - - - 
 Age (≥50 v. <50), 
years
1.31
(0.88 - 1.94)
0.18 1.64
(1.07 - 2.53)
0.03§ 1.41
(0.93 - 2.15)
0.11 1.79
(1.13 - 2.84)
0.01§
Sex (male v. female) 0.87
(0.58 - 1.30)
0.49 0.94
(0.61 - 1.47)
0.80 0.94
(0.62 - 1.44)
 0.79 1.02
(0.64 - 1.62)
0.94
 Cigarettes/day 
(<20 v. ≥20), n†
1.47
(0.98 - 2.21)
0.06 1.69
(1.07 - 2.65)
0.02§ 1.38
(0.90 - 2.14)
0.14 1.83
(1.12 - 2.98)
0.02§
FTND (<7 v. ≥7)‡ 2.03
(0.80 - 5.15)
0.14 1.59
(0.59 - 4.31)
0.36 1.59
(0.60 - 4.18)
0.35 1.21
(0.43 - 3.45)
0.72
 Age started smoking 
(≥20 v. <20), years
1.46
(0.93 - 2.31)
0.10 1.30
(0.79 - 2.13)
0.30 1.42
(0.88 - 2.28)
0.15 1.17
(0.70 - 1.97)
0.54
 Reinforcement 
assessment, PR v. NR
1.07
(0.60 - 1.90)
0.83 0.86
(0.46 - 1.63)
0.65 1.02
(0.56 - 1.86)
0.95 0.82
(0.42 - 1.58)
0.55
 Reinforcement assess-
ment, NR + PR v. NR
1.07
(0.64 - 1.78)
0.80 0.97
(0.56 - 1.69)
0.93 1.08
(0.64 - 1.83)
0.78 0.99
(0.56 - 1.76)
0.98
PPAR = point prevalence abstinence rate; CAR = continuous abstinence rate; OR = odds ratio; FTND = Fagerström test for nicotine dependence; NR = negative reinforcement (smoking to avoid 
a negative state); PR = positive reinforcement (smoking for pleasure); N/A = not applicable (never tried to quit).
*Adjusted for treatment and all other factors in the model.
†<20 cigarettes/day indicates light smokers; ≥20 cigarettes/day indicates heavy smokers.
‡FTND <7 indicates less nicotine dependence, and ≥7 indicates heavy nicotine dependence.
§Statistically significant.
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